Download PDF
Thromb Haemost 2012; 107(01): 4-5
DOI: 10.1160/TH11-11-0790
Invited Editorial Focus
Schattauer GmbH

Mild renal disease increases major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting

…or why clinical cardiologists and interventionalists should be friends
Greg Flaker
1   University of Missouri, Columbia, Missouri, USA
,
Arun Kumar
1   University of Missouri, Columbia, Missouri, USA
› Author Affiliations
Further Information

Publication History

Received: 08 November 2011

Accepted: 14 November 2011

Publication Date:
20 November 2017 (online)

    Permissions and Reprints

 

  • References

  • 1 Manzano-Fernández S, Cambronero F, Caro-Martínez C. et al. Mild Kidney Disease is a Risk Factor for Major Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous coronary stenting. Thromb Haemost 2012; 107: 51-58.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Manoukian S, Feit F, Mehran R. et al. Impact of major bleeding on 30-Day mortality and clinical outcomes in patients with acute coronary syndromes: analysis from the ACUITY trial. JACC 2007; 49: 1362-1368.
    CrossrefPubMedGoogle Scholar
  • 3 De Caterina R, Connolly S, Chrolavicius S. et al. on behalf of the ACTIVE Investigators. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J 2010; 31: 2133-2140.
    CrossrefPubMedGoogle Scholar
  • 4 Marinigh R, Lane DA, Lip GY.. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57: 1339-1348.
    CrossrefPubMedGoogle Scholar
  • 5 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 To AC, Yehia M, Collins JF.. Atrial fibrillation in Haemodialysis patients: do the guidelines for anticoagulation apply?. Nephrology 2007; 12: 441-447.
    CrossrefPubMedGoogle Scholar
  • 7 Fang MC, Go AS, Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage. JACC 2011; 58: 395-401.
    CrossrefPubMedGoogle Scholar
  • 8 Lip GY, Huber K, Anderotti F. et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103: 13-28. [Erratum in Thromb Haemost 2010; 104: 653.]
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patient with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-579.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Alexander J, Lopes R, James S. et al. for the APPRAISE-2 Investigators. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med 2011; 365: 699-708.
    CrossrefPubMedGoogle Scholar